[HTML][HTML] Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders
C Okhuijsen-Pfeifer, MZ van der Horst… - Translational …, 2022 - nature.com
Clozapine is the most effective antipsychotic for patients with treatment-resistant
schizophrenia. However, response is highly variable and possible genetic underpinnings of
this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to
estimate the amount of variance in symptom severity among clozapine-treated patients
explained by PRSs (R2) and examined the association between symptom severity and
genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activity. Genome-wide …
schizophrenia. However, response is highly variable and possible genetic underpinnings of
this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to
estimate the amount of variance in symptom severity among clozapine-treated patients
explained by PRSs (R2) and examined the association between symptom severity and
genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activity. Genome-wide …
[PDF][PDF] Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorder
B Lin, CRC Group& - scholar.archive.org
However, response is highly variable and possible genetic underpinnings of this variability
remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate the
amount of variance in symptom severity among clozapine-treated patients explained by
PRSs
remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate the
amount of variance in symptom severity among clozapine-treated patients explained by
PRSs
以上显示的是最相近的搜索结果。 查看全部搜索结果